Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Cantor Fitzgerald
Johnson and Johnson
Citi
QuintilesIMS
Fuji
Chinese Patent Office
Healthtrust
Argus Health
Merck

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,192,938

« Back to Dashboard

Which drugs does patent 7,192,938 protect, and when does it expire?


Patent 7,192,938 protects BONIVA and ACTONEL and is included in two NDAs. There have been zero Paragraph IV challenges on Actonel and

Protection for ACTONEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-five patent family members in thirty-two countries.

Summary for Patent: 7,192,938

Title:Method of treatment using bisphosphonic acid
Abstract:The present invention refers to a pharmaceutical composition of a bisphosphonic acid or salt thereof, and an excipient thereof, and a method of treating disorder characterized by pathologically increased bone resorption comprising orally administering at least 150% of the expected efficious daily dose of a bisphosphonic acid or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients thereof and administering the dose at a period of one two or three consecutive days per month.
Inventor(s): Bauss; Frieder (Neuhofen, DE), Pichler; Bernhard (Ketsch, DE), Turley; Stephen (Bottmingen, CH)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:10/998,849
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Hoffmann La RocheBONIVAibandronate sodiumTABLET;ORAL021455-002Mar 24, 2005ABRXYesYes► Subscribe► Subscribe► SubscribeTREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID
ApilACTONELrisedronate sodiumTABLET;ORAL020835-005Apr 22, 2008ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,192,938

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
02010136May 10, 2002

Non-Orange Book Patents for Patent: 7,192,938

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,410,957Method of treatment using bisphosphonic acid► Subscribe
7,718,634Method of treatment using bisphosphonic acid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,192,938

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2763775► Subscribe
China1646193► Subscribe
China100551377► Subscribe
China1939314► Subscribe
Cyprus1108105► Subscribe
Cyprus1116233► Subscribe
Denmark1880744► Subscribe
Germany60317061► Subscribe
Denmark1506041► Subscribe
EcuadorSP045335► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Cantor Fitzgerald
Argus Health
Cerilliant
Mallinckrodt
US Army
Chubb
Deloitte
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot